PHILADELPHIA--(BUSINESS WIRE)--Xylos Corporation will present its biocellulose technology, clinical validations and business update to a combined group of venture capital firms and strategic partners at the In3 Medical Device Summit in Las Vegas (February 28, 2008 at 9:40am - Venetian Hotel). Mark S. McNulty, CEO, will provide an overview of the Company’s core biomaterial and describe its array of enabling technologies that allow Xylos to uniquely develop surgical implants designed to meet surgeon-defined performance and handling characteristics. Mr. McNulty explains, “The versatility of our biomaterial and our ability to bioengineer it to achieve the specific requirements needed by surgeons allows us to uniquely shift the paradigm for surgical implants. Our new class of biomaterial does not possess the shortfalls and limitations inherent in current materials from human, animal and petrochemical-based sources.”
